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Summary
The bifunctional trypanothione synthetase-amidase
(TRYS) comprises two structurally distinct catalytic
domains for synthesis and hydrolysis of trypan-
othione (N 1,N 8-bis(glutathionyl)spermidine). This
unique dithiol plays a pivotal role in thiol-redox
homeostasis and in defence against chemical and
oxidative stress in trypanosomatids. A tetracycline-
dependent conditional double knockout of TRYS
(cDKO) was generated in bloodstream Trypanosoma
brucei. Culture of cDKO parasites without tetracycline
induction resulted in loss of trypanothione and accu-
mulation of glutathione, followed by growth inhibition
and cell lysis after 6 days. In the absence of inducer,
cDKO cells were unable to infect mice, conﬁrming that
this enzyme is essential for virulence in vivo as well as
invitro.Toestablishwhetherbothenzymaticfunctions
were essential, an amidase-dead mutant cDKO line
was generated. In the presence of inducer, this line
showeddecreasedgrowthinvitroanddecreasedviru-
lence in vivo, indicating that the amidase function is
not absolutely required for viability. The druggability
of TRYS was assessed using a potent small molecule
inhibitor developed in our laboratory. Growth inhibi-
tion correlated in rank order cDKO, single KO, wild-
type and overexpressing lines and produced the
predicted biochemical phenotype. The synthetase
function of TRYS is thus unequivocally validated as a
drug target by both chemical and genetic methods.
Introduction
The protozoan parasite Trypanosoma brucei is the caus-
ative agent of human African trypanosomiasis (HAT),
commonly known as sleeping sickness. This disease,
thought to be largely controlled in the 1960s, has
re-emerged as a major threat to human health due to a
number of factors including lack of ﬁnancial resources,
conﬂict in affected countries and failure to adequately
monitor infection. Currently, the World Health Organisa-
tion reports that over 400 000 people are infected with
HAT, resulting in an annual death toll of more than
50 000 (Stuart et al., 2008). In the absence of an effec-
tive vaccine, treatment is solely dependent upon a piti-
fully small repertoire of drugs which suffer from a
number of problems including severe toxic side-effects
(Fairlamb, 2003) and acquired drug resistance (Barrett
and Fairlamb, 1999). To compound these difficulties,
many of the current chemotherapeutic treatments also
require lengthy periods of hospitalization and are pro-
hibitively expensive (Stuart et al., 2008). With no new
drugs for the treatment of HAT in the pipeline, a con-
certed effort is being made to identify, characterize and
validate novel molecular targets urgently required for
drug discovery.
In the search for anti-parasitic drug targets, metabolic
pathways that are both essential for parasite survival
and absent from the host are logical starting points (El
Sayed et al., 2005). One such pathway is the thiol
metabolism of trypanosomes and Leishmania. These
parasites are uniquely dependent upon trypanothione
(N 1,N 8-bis(glutathionyl)spermidine, T[SH]2) as their prin-
cipal thiol, in contrast to most other organisms (including
their mammalian hosts) which utilize glutathione (g-L-
glutamyl-L-cysteinylglycine, GSH) (Fairlamb et al., 1985).
This dithiol is primarily responsible for the maintenance
of thiol-redox homeostasis within trypanosomatids, and
is involved in a number of critical cellular processes
including deoxyribonucleotide synthesis (Dormeyer
et al., 2001), and defence against oxidative stress (Ariy-
anayagam and Fairlamb, 2001) and xenobiotics (Vickers
et al., 2004). Trypanothione has also been implicated
in the mode of action as well as the mechanism of
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(Mukhopadhyay et al., 1996; Wyllie et al., 2004; Croft
et al., 2006) and in defence against chemical and
oxidant stress induced by arsenicals and nifurtimox in
T. brucei (Fairlamb et al., 1989; Ariyanayagam et al.,
2005; Alibu et al., 2006). Therefore, in an attempt to
exploit this essential and unique metabolite, T[SH]2-
dependent and biosynthetic enzymes have become a
major focus for drug discovery.
The pivotal role of T[SH]2 metabolism in the viability and
virulence of trypanosomatids has been unequivocally
demonstrated using genetic techniques such as classical
gene knockout and RNA interference (RNAi).
Trypanothione-dependent enzymes that have been vali-
dated as potential drug targets using these methodologies
include: trypanothione reductase (Tovar et al., 1998;
Krieger et al., 2000), tryparedoxin (Wilkinson et al., 2003)
and tryparedoxin peroxidase (Wilkinson et al., 2003).
Unsurprisingly, the enzyme responsible for the biosynthe-
sis of T[SH]2, the bifunctional trypanothione synthetase-
amidase (TRYS), has also been conﬁrmed as essential
for the viability and proliferation of T. brucei bloodstream
(Comini et al., 2004) and procyclic forms (Ariyanayagam
et al., 2005) by RNAi. In pathogenic trypanosomatids,
TRYS catalyses the synthesis of T[SH]2 from GSH and
spermidine in a two-step, ATP-dependent reaction via a
glutathionylspermidine intermediate. In addition to this
role in biosynthesis, the N-terminal domain of TRYS also
functions as an amidase, hydrolysing T[SH]2 to GSH and
spermidine, again via glutathionylspermidine. The bio-
logical signiﬁcance of TRYS-amidase, classiﬁed as a
cysteine–histidine-dependent aminohydrolase/peptidase
amidase (Bateman and Rawlings, 2003; Rigden et al.,
2003), is not fully understood. However, it has been sug-
gested that the conﬂicting biosynthetic and hydrolytic
functions of this enzyme may enable the parasite to
respond to ﬂuctuating cellular requirements for both
T[SH]2 and polyamines, essential for proliferation and dif-
ferentiation (Fairlamb and Cerami, 1992; Bacchi and
Yarlett, 1995).
In the current study, we assessed the essentiality of
TRYS by classical gene replacement to fulﬁl the stringent
target validation criteria of the University of Dundee Drug
Discovery Unit (Frearson et al., 2007). Gene replacement
is the preferred method of genetic validation because
‘off-target’ effects cannot be ruled out using RNAi. More-
over, target knock-down by RNAi does not permit inde-
pendent analysis of bifunctional enzymes such as
DHFR-TS (Sienkiewicz et al., 2008) or TRYS. Using a
combination of classical gene replacement, mutagenesis
and chemical intervention methods, we dissect the oppos-
ing synthetic and hydrolytic functions of TRYS in order to
independently study their respective roles in T. brucei cell
virulence and viability.
Results and discussion
Generation of TRYS conditional null mutants
To date, the essentiality of T. brucei trypanothione syn-
thetase (TRYS) has only been demonstrated by RNAi
(Comini et al., 2004; Ariyanayagam et al., 2005), a meth-
odology that lacks the robustness of classical gene
replacement. With this in mind, we sought to deﬁnitively
classify this enzyme as a drug target in bloodstream try-
panosomes by replacing TRYS with drug-resistance
genes (Fig. 1A). Previous studies have demonstrated that
TRYS is present as a single-copy gene per haploid
genome of T. brucei (Oza et al., 2003). The ﬁrst TRYS
gene copy was replaced with the puromycin N-acetyl
transferase (PAC) gene by homologous recombination
and subsequent selection for puromycin resistance, gen-
erating a single knockout (SKO) cell line. Attempts to
create a null mutant by directly replacing the second
allelic copy with the hygromycin-resistance gene (hygro-
mycin phosphotransferase, HYG) proved unsuccessful,
suggesting that TRYS is indeed essential for the viability
of T. brucei bloodstream parasites. Consequently, a con-
ditional double knockout (cDKO) cell line was generated
by introducing an ectopic and tetracycline-inducible copy
of TRYS prior to replacing the second copy with HYG.
This ectopic copy of TRYS was inserted into the rDNA
locus of the SKO cell line using a pLew 100 vector encod-
ing a blasticidin-resistance gene (BSD) followed by dele-
tion of the second genomic copy with HYG. As the
modiﬁed T. brucei 427 cell line [wild-type (WT)] used in
this study constitutively expresses the T7 RNA poly-
merase and the tetracycline repressor protein, the result-
ing cell line was a TRYS conditional null mutant where
TRYS expression depends on the presence of tetracy-
cline (cDKO). Southern blot analysis of genomic DNA
from cell lines generated at each stage of this process
conﬁrmed the validity of the TRYS conditional null mutant
(Fig. 1B).
TRYS is essential in bloodstream T. brucei in vitro
In HMI9-T culture medium, no signiﬁcant difference could
be detected between the growth rates of the WT and SKO
cells, with generation times of 9.6  0.1 and 9.5  0.2 h
respectively (data not shown). Indeed, the cDKO cell line,
grown in the presence of tetracycline, showed no marked
growth phenotype with a doubling time of 9.9  0.02 h
(Fig. 2A). Following the removal of tetracycline from the
medium, cDKO cells continued to grow exponentially for
3 days. Growth slowed by day 4 of culture with all cells
ﬁnally dying by day 8. To determine the actual point where
cDKO parasites grown in the absence of tetracycline com-
pletely lose viability, cells were subcultured each day into
medium containing tetracycline. Up to the 6th day of
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cline; however, beyond this point no viable cDKO cells
could be recovered on culture for a further 10 days.
Failure of this cell line to grow in the absence of the
tetracycline-induced expression of TRYS conﬁrms that
this enzyme is essential for bloodstream T. brucei viability.
Interestingly, ectopic expression of the L. major TRYS
was equally capable of complementing for the loss of
endogenous TRYS in the cDKO cell line (Fig. S1). The
fact that loss of TRYS activity is trypanocidal rather than
cytostatic is highly advantageous from a drug discovery
perspective because drug therapy is not dependent on a
fully functional immune response (Frearson et al., 2007).
Biochemical analyses of TRYS cDKO cells
The ‘slow death’ phenotype of cDKO cells following the
removal of tetracycline may be partly explained by the low
turnover of TRYS or its product, T[SH]2. Western blot
analysis of whole cell extracts revealed that although the
levels of this enzyme declined following the removal of
tetracycline, it was not until day 6 that TRYS was no
longer detectable (Fig. 2B). This observation suggests
that the rate of turnover of TRYS (or T[SH]2) is very low in
T. brucei and that TRYS (or T[SH]2) is only removed from
the cell by dilution due to cell division in the absence of
further protein synthesis. Nevertheless, the death of
cDKO cells coinciding with the disappearance of TRYS
once again conﬁrms that this enzyme is essential in
bloodstream trypanosomes.
The effect of TRYS depletion on intracellular thiols was
studied by high-performance liquid chromatography
(HPLC). Due to the number of cells required for this analy-
sis, thiols could only be monitored in cultures for 4 days
following the removal of tetracycline. The cessation of
ectopic TRYS expression within these parasites had a
pronounced effect on intracellular thiol levels (Fig. 2C).
Glutathione, the substrate of TRYS, accumulated in cDKO
cells in the absence of tetracycline, such that after 4 days,
levels had reach 160% of those seen in control cells
(cDKO cells plus tetracycline). In contrast, T[SH]2 and
glutathionylspermidine, the products of this enzyme reac-
tion, fell considerably. Indeed, T[SH]2 levels within these
parasites fell to 16.5% of control levels. As 4 day cultures
showed only minimally retarded growth in comparison
with control cells, it would appear that bloodstream trypa-
nosomes, at least in vitro, can survive with vanishingly
small amounts of T[SH]2. However, it should be noted that
the HMI9-T culture medium used in these studies is rich in
reducing agents such as thioglycerol (56 mM) and cys-
teine (1.5 mM) which may protect these thiol-depleted
cells from oxidant stress.
Virulence of cDKO parasites in mice
The oxidative environment in vivo is signiﬁcantly different
from in vitro culture conditions, underlining the importance
of carrying out drug target validation studies in appropri-
ate animal models (Frearson et al., 2007). With this in
mind, groups of mice were inoculated with WT, cDKO or
cDKO parasites which had been grown in the absence of
tetracycline for 24 h. Mice infected with tetracycline-
treated parasites were dosed with doxycycline in their
drinking water 5 days prior to, and throughout infection to
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Fig. 1. Genotypic analysis of WT, SKO and cDKO cell lines.
A. Schematic representation of the stepwise generation of the
TRYS cDKO cell line in T. brucei. (i) One allele of TRYS was
replaced with the puromycin-resistance gene (PAC) by homologous
recombination, generating DTRYS::PAC cell line (SKO); (ii) a
tetracycline-inducible ectopic copy of TRYS was introduced into the
rDNA, generating TRYS
TiDTRYS::PAC cell line; (iii) while
tetracycline induces the expression of the ectopic copy, the
remaining allele was replaced with a hygromycin resistance gene
(HYG) by homologous recombination, resulting in conditional
double knockout cell line TRYS
TiDTRYS::PAC/DTRYS::HYG
(cDKO).
B. Conﬁrmation of genotype of T. brucei TRYS conditional double
knockout cell line. Southern blot analysis of PstI-digested genomic
DNA (~5 mg) from wild-type T. brucei cells (lane 1), DTRYS::PAC
(lane 2), TRYS
TiDTRYS::PAC (lane 3) and
TRYS
TiDTRYS::PAC/DTRYS::HYG (lane 4) cells; the TRYS ORF
probe shows allelic TbTRYS at 3 kb and the ectopic copy
TbTRYS
Ti at ~10 kb.
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monitored over a 30 day period and survival curves of
each infection are shown in Fig. 3. Mice infected with WT
parasites succumbed to infection on day 5 and this was
also the case for mice infected with cells expressing
ectopic TRYS (cDKO plus doxycycline). In contrast, four
out of ﬁve mice infected with cDKO cells in the absence of
doxycycline remained completely free of parasites
beyond 30 days while the remaining mouse from this
group only showed a lethal parasitaemia on day 23.
Western blot analysis of cells recovered from this infected
mouse conﬁrmed that these parasites had regained
expression of TRYS, suggesting that tetracycline control
had been lost, a common phenomenon in conditional null
mutants of essential genes in T. brucei (Chang et al.,
2002; Roper et al., 2002). Collectively, these results
conﬁrm that TRYS is essential for parasite survival in a
mammalian host.
Chemical validation of TRYS as a drug target in
T. brucei
Genetic validation is a crucial ﬁrst step in the identiﬁcation
of a drug target. However, the importance of demonstrat-
ing that a target is ‘druggable’ within a cell should not be
underestimated. As a result of a high-throughput drug
screening and medicinal chemistry campaign carried out
by the Drug Discovery Unit in Dundee, DDU 86439 (N-(3-
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Fig. 2. Growth characteristics and biochemical analysis of cDKO cells in vitro.
A. The growth of the cDKO cell line in HMI9-T media was monitored in the presence (closed circles) and absence of tetracycline (open circles,
dashed line). The arrow indicates the point where the viable cells are no longer recoverable when subcultured for up to 10 days in medium
containing tetracycline.
B. Immunoblots of cell extracts of WT, SKO and cDKO (plus and minus tetracycline) cells were probed with antiserum to T. brucei TRYS and
to T. brucei PTR1 as a control (1 ¥ 10
7 parasites in each lane).
C. Intracellular T[SH]2 (closed circles) and GSH (open circles) levels in cDKO cells following the removal of tetracycline from cultures. Initial
levels of T[SH]2 and GSH in untreated cells were 0.42 and 0.54 nmol(10
8 cells)
-1 respectively. Each data point represents the
means  standard deviations from triplicate determinations.
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1-yl)acetamide, Fig. 4A) was identiﬁed as a potent inhibi-
tor of recombinant T. brucei TRYS with an IC50 of 45 nM
(full details are to be published elsewhere). This com-
pound inhibited the growth of WT cells in HMI9-T media
with an EC50 value of 7.0  0.2 mM following a 72 h
exposure. To conﬁrm that TRYS was speciﬁcally targeted
by this compound, TRYS SKO and overexpressing (OE)
cell lines were compared with WT cells for their relative
sensitivity to compound DDU 86439. Western analysis
and densitometry demonstrated that TRYS protein levels
were approximately twofold lower in SKO cells (Fig. 2B)
and threefold higher in OE cells as compared with WT
levels (Fig. S2). Changes in the level of TRYS in these
cells correlated well with their relative sensitivity to com-
pound DDU 86439 with EC50 values of 1.2  0.04 and
23.0  0.4 mM for SKO and OE cell lines respectively
(Fig. 4B). cDKO cells, grown in the absence of tetracy-
cline for 2 days prior to analysis, were found to be hyper-
sensitive to this compound (EC50 0.46  0.01 mM,
Fig. 4B), providing further evidence that TRYS is the spe-
ciﬁc target of this inhibitor.
Intracellular thiol levels were determined in WT para-
sites following incubation with concentrations of the TRYS
inhibitor corresponding to 0.5, 1.0, 1.5 and 2.0 times the
established EC50 value (7 mM) (Fig. 4C). Treatment with
DDU 86439 resulted in a signiﬁcant, dose-dependent
decrease in the levels of intracellular T[SH]2. Trypano-
somes incubated with the highest levels of this compound
(14 mM) were found to maintain only 5% of their original
T[SH]2 levels after 72 h. As in the case of cDKO cells
(Fig. 2B), the absence of functional TRYS in drug-treated
cells led to an accumulation of GSH, with levels reaching
fourfold higher than those seen in untreated cells. The
greater speed and magnitude of these effects are consis-
tent with the acute effects of chemical inhibition compared
with the slower effects of loss of target activity by genetic
intervention (Fig. 2D). These observations also suggest
that the minimum concentration of T[SH]2 compatible with
survival is ~3 mM [Table S3, assuming 108 cells = 5.8 ml
(Opperdoes et al., 1984)].
Is the amidase activity of TRYS essential to
bloodstream T. brucei?
Following the unequivocal chemical and genetic valida-
tion of the synthetase activity of TRYS as a drug target in
bloodstream T. brucei, we posed the question: could this
bifunctional enzyme actually embody two drug targets in
one? Comparatively little is known about the amidase
activity of TRYS and its biological function remains
unclear. In previous kinetic and structural studies, a cys-
teine at position 59 of the equivalent Crithidia fasiculata
(Oza et al., 2002a) and L. major (Fyfe et al., 2008)
enzymes has been demonstrated as critical in the cata-
lytic mechanism of the TRYS-amidase. Replacement of
cysteine 59 with an alanine in the Crithidia enzyme
resulted in a functional synthetase devoid of amidase
activity. To determine the role of TRYS-amidase in para-
site viability and virulence, this knowledge was exploited
to generate a TRYS conditional null mutant cell line
(cDKO(C57A)) expressing an amidase-‘dead’ enzyme
under tetracycline control (Fig. S3).
The amidase dead cell line was viable in HMI9-T
medium in the presence of tetracycline with a generation
time of 11.1  0.1 h (Fig. 5A), marginally slower than the
original cDKO line (9.9  0.02 h). Removal of tetracycline
again resulted in the slow death of parasites over an 8 day
period with viability being lost on day 6 of culture, con-
ﬁrming that TRYS synthetase, but not amidase activity is
essential for growth in vitro. In an identical manner to the
cDKO cell line, intracellular T[SH]2 levels fell following the
removal of tetracycline from cDKO(C57A) cultures while
GSH steadily accumulated (Fig. 5B). Parasites express-
ing the amidase-dead TRYS were markedly less virulent
in mice than those expressing the functional enzyme
(Fig. 5C). All ﬁve mice infected with cDKO(C57A) gradu-
ally succumbed to infection over a 9 day period, from day
6–15, while cDKO-infected animals died on day 5. The
parasites recovered from cDKO(C57A)-infected mice con-
tinued to express the mutated form of the TRYS enzyme,
as determined by PCR sequence analysis of genomic
DNA (data not shown). Four out of ﬁve mice infected with
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Fig. 3. Virulence of cDKO parasites in mice. Groups of ﬁve mice
were infected with either WT or cDKO cells (1 ¥ 10
4 parasites).
Mice infected with tetracycline-treated parasites were dosed with
doxycycline in their drinking water 3 days prior to, and throughout,
the infection. Data are presented in the form of a Kaplan–Meier
survival plot. Symbols: WT, blue; cDKO in the presence of
doxycycline, red; cDKO in absence of doxycycline, green.
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remained free of parasites for more than 20 days before
becoming terminally infected, while one mouse remained
parasite-free for the entire 30 days of the experiment.
Western and PCR analysis of parasites recovered from
the infected animals revealed that tetracycline control had
once again been lost and the mutated TRYS was being
freely expressed (data not shown). While it is evident that
TRYS-amidase activity is not essential for the in vivo or in
vitro viability of T. brucei, the absence of this activity
retards growth in vitro and decreases virulence in the
mouse model.
What is the biological function of TRYS-amidase in
T. brucei?
As TRYS-amidase is not required for the viability or viru-
lence of bloodstream T. brucei, the question of its bio-
logical function remains. Several researchers have
suggested that the ability to hydrolyse T[SH]2 to its com-
ponents, GSH and spermidine may enable cells to
respond to conditions of polyamine deprivation (Oza
et al., 2002b; Fyfe et al., 2008). To examine this hypoth-
esis, cDKO and cDKO(C57A) cell lines were tested
for their relative sensitivity to diﬂuoromethylornithine
(DFMO) (Fig. 6A), a suicide inhibitor of ornithine decar-
boxylase, the rate-determining enzyme in polyamine bio-
synthesis (Phillips and Wang, 1987; Phillips et al., 1988).
Should the primary role of TRYS-amidase be to release
polyamine stores from T[SH]2 in times of need, it would
be reasonable to assume that cells without this ability
would be more sensitive to DFMO. However, the cell
line expressing the functional TRYS-amidase was just
as sensitive to DFMO as the cell line expressing the
‘dead’ enzyme (EC50: 17.5  0.5 and 16.6  0.8 mM
respectively).
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Fig. 4. Chemical targeting of TRYS in T. brucei.
A. Chemical structure of TRYS inhibitor DDU 86439 (N-(3-(dimethylamino)propyl)-2-(3-(3-ﬂuorophenyl)-1H-indazol-1-yl)acetamide).
B. EC50 values were determined for DDU 86439 against WT (closed circles), SKO (open squares), TRYS-overexpressing (open circles) and
cDKO cells grown in the absence of tetracycline for 2 days prior to analysis (closed squares, dotted line). The curves are the non-linear ﬁts of
data using a two-parameter EC50 equation provided by GraFit (see Experimental procedures). EC50 values of 7.1  0.2, 1.2  0.05, 23.3  0.3
and 0.46  0.01 mM were determined for WT, SKO, TRYS-overexpressing and cDKO cell lines respectively. Data are the mean of duplicate
measurements.
C. Analysis of intracellular T[SH]2 (closed circles) and GSH (open circles) levels in T. brucei bloodstream parasites (WT) following incubation
with compound DDU 86439 (72 h). Data are represented as a percentage of the thiol levels of untreated cells (0.51 and 0.42 nmol(10
8 cells)
-1
for GSH and T[SH]2 respectively; Table S1) and each measurement is the mean of three individual measurements.
534 S. Wyllie etal. 
© 2009 The Authors
Journal compilation © 2009 Blackwell Publishing Ltd, Molecular Microbiology, 74, 529–540To determine whether the reduced virulence of the
cDKO(C57A) cell line could be attributed to an inability to
access T[SH]2-conjugated polyamines, groups of
cDKO(C57A)-infected mice were given a daily bolus of
spermidine via intraperitoneal injection. Previous studies
have shown that dosing of mice in this manner increased
parasite polyamine levels to such an extent that DFMO
could no longer cure infection (McCann et al., 1981;
Nathan et al., 1981). Similarly, we hypothesized that
increased polyamine levels in cDKO(C57A) cells may
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Fig. 5. In vitro and in vivo characterization of a TRYS-amidase ‘dead’ cell line.
A. The growth of the cDKO(C57A) cell line in HMI9-T medium was monitored in the presence (closed circles) and absence of tetracycline
(open circles, dashed line).The arrow indicates the point where the viable cells are no longer recoverable when subcultured for up to 10 days
in medium containing tetracycline.
B. Intracellular T[SH]2 (closed circles) and GSH (open circles) levels in cDKO(C57A) cells following the removal of tetracycline from cultures.
Each data point represents the means  standard deviations from triplicate determinations.
C. Groups of ﬁve mice were infected with either WT or cDKO(C57A) cells (1 ¥ 10
4 parasites). Mice infected with tetracycline-treated parasites
were dosed with doxycycline in their drinking water 3 days prior to, and throughout, the infection. Data are presented in the form of a
Kaplan–Meier survival plot. Symbols: WT, blue; cDKO in the presence of doxycycline, red; cDKO in absence of doxycycline, green.
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Fig. 6. The effect of polyamines on the growth and virulence of cDKO(C57A) parasites.
A. EC50 values were determined for DFMO against cDKO (closed circles) and cDKO(C57A) cells (closed circles). The curves are the
non-linear ﬁts of data using a two-parameter EC50 equation provided by GraFit (see Experimental procedures). EC50 values of 17.5  0.5 and
16.6  0.8 mM were determined for cDKO and cDKO(C57A) cell lines respectively. Data are the mean of duplicate measurements.
B. Groups of ﬁve mice were infected with either cDKO or cDKO(C57A) cells (1 ¥ 10
4 parasites). All mice were infected with tetracycline-treated
parasites and dosed with doxycycline in their drinking water. One set of the cDKO and cDKO(C57A)-infected mice received daily
intraperitoneal injections of spermidine (100 mg kg
-1). Data are presented in the form of a Kaplan–Meier survival plot. Symbols: cDKO, blue;
cDKO plus spermidine, red; cDKO(C57A), green; cDKO(C57A) plus spermidine, yellow.
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infections. Mice inoculated with the cDKO cell line suc-
cumbed to infection on days 4 and 5, regardless of the
presence or absence of additional spermidine (Fig. 6B).
Once again, the cDKO(C57A) parasites were less virulent
than those expressing a functional TRYS-amidase, with
mice becoming heavily infected between days 6 and 10.
Most signiﬁcantly, daily dosing of infected mice with sper-
midine had absolutely no effect on the virulence of the
cDKO(C57A) cells. The failure of additional spermidine to
enhance the virulence of these cells could suggest that
the primary function of TRYS-amidase is not to enable
access to T[SH]2-conjugated polyamines.
These ﬁndings bring into question the hypothesis that
TRYS-amidase plays a pivotal role in the regulation of
cellular polyamines (Shim and Fairlamb, 1988; Tetaud
et al., 1998; Oza et al., 2002b; Fyfe et al., 2008). If this is
not the case, then what is the biological function of the
amidase in T. brucei? Kinetic analysis of recombinant
T. brucei and T. cruzi TRYS has shown that the amidase
activity of these enzymes is equivalent to less than 1% of
the synthetase activity under optimal assay conditions
(Oza et al., 2002b; 2003). Should this also be true of the
in vivo enzyme, it is difficult to see how the amidase could
have any meaningful impact on intracellular polyamine
levels. Alternatively, the low enzymatic activity of recom-
binant TRYS-amidase could be readily explained if T[SH]2
and GspdSH were not the natural substrates of this
enzyme. In the Gram-positive bacteria Mycobacterium
smegmatis, a thiol S-conjugate amidase has been char-
acterized which speciﬁcally hydrolyses thiol-conjugated
xenobiotics, resulting in detoxiﬁcation of the xenobiotic
and recycling of the thiol (Newton et al., 2000). It is tempt-
ing to suggest that TRYS-amidase may play a similar role
in T. brucei and that this enzyme is highly selective for
S-conjugates of T[SH]2 formed by trypanothione
S-transferase (Vickers and Fairlamb, 2004). Studies are
underway to test the validity of this hypothesis. What is
irrefutable from this study is that TRYS-amidase is not a
viable drug target in the African trypanosome.
Implications for parasite chemotherapy
In this study, TRYS has been chemically and genetically
validated as a drug target in bloodstream T. brucei.W e
have shown that TRYS null trypanosomes are unable to
establish an infection in mice and that chemical targeting
of this enzyme leads to parasite death. The potency of our
lead TRYS inhibitor against bloodstream trypanosomes
(EC50 7 mM) compares favourably with that of eﬂornithine
(EC50 17.5 mM, Fig. 6A), a current front-line drug used in
the treatment of HAT. Like eﬂornithine, DDU 86439 is not
rapidly cidal and the decrease of intracellular T[SH]2
content is compatible with dilution due to cell division
rather than high metabolic turnover. Given that many
existing drugs interact directly or indirectly with T[SH]2
metabolism (Fairlamb, 2003), inhibitors of TRYS could
prove ideal candidates for combination therapy. RNAi
studies have revealed that TRYS-depleted T. brucei pro-
cyclics are signiﬁcantly more susceptible to trypanocides,
such as melarsoprol and triostam, also known to act on
T[SH]2 metabolism (Ariyanayagam et al., 2005). In addi-
tion, these procyclics were also more sensitive to the
redox-cycling drug nifurtimox, currently in phase III clinical
trials for use against African sleeping sickness. Collec-
tively, these ﬁndings suggest that the use of drugs target-
ing TRYS, in combination with existing drugs, could prove
an effective strategy in treating T. brucei infections.
Experimental procedures
Cell lines and culture conditions
Trypanosoma brucei bloodstream-form ‘single marker’ S427
(T7RPOL TETR NEO) and knockouts were cultured at 37°C
in modiﬁed HMI9 medium (56 mM 1-thioglycerol was substi-
tuted for 200 mM 2-mercaptoethanol) supplemented with
2.5 mgm l
-1 G418 to maintain expression of T7 RNA poly-
merase and the tetracycline repressor protein (Hirumi and
Hirumi, 1989). Cultures were initiated with 1 ¥ 10
5 cells ml
-1
and subcultured when cell densities approached
1–2 (¥ 10
6)m l
-1. Single marker (WT), SKO, cDKO and OE
cell lines were also grown continuously in the presence of the
appropriate drug selection (see below for further details).
In order to examine the effects of inhibitors on the growth of
these parasites, triplicate cultures containing the inhibitor
were seeded at 1 ¥ 10
5 trypanosomes ml
-1. Cell densities
were determined using the CASY Model TT cell counter
(Schärfe) after culture for 72 h. EC50 values were determined
using the following two-parameter equation by non-linear
regression using GraFit:
y =
+
[] ⎛
⎝
⎞
⎠
100
1
50
I
EC
m
where the experimental data were corrected for background
cell density and expressed as a percentage of the uninhibited
control cell density. In this equation [I] represents inhibitor
concentration and m is the slope factor.
Generation of knockout, overexpression and recovery
constructs
The primers used are summarized in Table 1 and were
designed using the T. brucei trypanothione synthetase
(TRYS) sequence in GeneDB (Tb927.2.4370) as a template.
The accuracy of all assembled constructs was veriﬁed by
sequencing. TRYS gene replacement cassettes were gener-
ated by amplifying a region of DNA encompassing the
5′-UTR, open reading frame (ORF) and 3′-UTR of T. brucei
TRYS from genomic DNA with primers 5′UTR-NotI_s and
3′UTR-NotI_as, using Pfu polymerase. This sequence was
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regions used in the assembly of replacement cassettes con-
taining the selectable drug-resistance genes puromycin
N-acetyl transferase (PAC) and hygromycin phosphotrans-
ferase (HYG), exactly as previously described (Martin and
Smith, 2005).
To generate the recovery construct pLew100_TbTRYS, the
TRYS ORF from T. brucei was ampliﬁed from genomic DNA
using TbTRYS-HindIII sense and TbTRYS-BamHI antisense
primers, and cloned into pCR-Blunt II TOPO (Invitrogen). The
pCR-Blunt II-TOPO-TbTRYS construct was then digested
with HindIII and BamHI and the resulting fragment ligated into
the HindIII/BamHI cloning site of a modiﬁed pLew100
tetracycline-inducible expression vector (Wirtz et al., 1999)
which contains blasticidin S transferase (BSD) as the select-
able gene marker (kindly supplied by Dr Kirstee Martin). The
resulting rescue vector was also used as a TRYS overex-
pression vector in single marker T. brucei bloodstream
parasites.
An additional recovery construct was generated containing
a mutated version of the T. brucei TRYS gene. Site-directed
mutagenesis was carried out following the QuikChange
® pro-
tocol (Stratagene) and using the KOD HotStart DNA poly-
merase (Novagen). Using the pLew100_TbTRYS construct
as a template,aCt oAmutation was introduced at position 57
of T. brucei TRYS was generated by PCR resulting in the
modiﬁed construct – pLew100_TbTRYS(C57A).
Generation of transgenic T. brucei cell lines
Knockout, recovery and overexpression constructs were pre-
pared using QIAprep Miniprep Plasmid Kit (Qiagen). DNA
was digested with NotI, ethanol precipitated and redissolved
in sterile water at a ﬁnal concentration of 1 mg ml
-1. Trypano-
somes were electroporated with 5 mg of DNA using reagents
from the Human T cell Nucleofector kit as per manufacturers’
instructions and using programme X-001 of the Nucleofector
II electroporator (Amaxa, Cologne, Germany) (Burkard et al.,
2007).
The cDKO of TRYS was generated by sequentially replac-
ing the endogenous TRYS genes with drug-resistance genes.
The ﬁrst TRYS allele was replaced with the drug-resistance
gene PAC resulting in a SKO cell line which was cultured in
the continuous presence of 0.1 mgm l
-1 puromycin. The SKO
cells were then transformed with either the recovery vector
pLew100_TbTRYS or the mutated version of this vector
pLew100_TbTRYS(C57A) and cultured in the presence of
2.5 mgm l
-1 blasticidin in addition to puromycin. Prior to
removal of the remaining TRYS allele, expression of the
recombinant TRYS proteins were induced by the addition of
tetracycline (2 mgm l
-1, 72 h) to the culture medium. A cDKO
cell line was ﬁnally generated following replacement of the
ﬁnal TRYS allele with an HYG. The resulting cell line was
cultured in the presence of hygromycin (4.0 mgm l
-1)i n
addition to the previously described drugs. The TRYS
overexpression cell line was generated by directly trans-
forming single marker bloodstream parasites with the
pLew100_TbTRYS vector and inducing recombinant protein
expression by the addition of tetracycline. At each step in the
generation of these transgenic cell lines, parasites were
cloned by serial dilution.
Southern blot analyses of transgenic T. brucei cell lines
The ORF of T. brucei TRYS was ampliﬁed by PCR (using the
primers previously described for the cloning of TbTRYS into
pLew100-BSD) and the PCR DIG Probe Synthesis Kit
(Roche). The resulting digoxigenin-labelled TbTRYS product
was used as a probe. Samples of genomic DNA (5 mg) from
single marker and transgenic cell lines were digested with the
restriction endonuclease PstI, the digestion products were
then separated on a 0.8% agarose gel and transferred on to
a positively charged nylon membrane (Roche). The mem-
brane was hybridized overnight in DIG Easy Hyb solution
(Roche) at 42°C with the DIG-labelled TRYS ORF probe (2 ml
of PCR product). Following hybridization, membranes were
washed twice in low stringency conditions (25°C, 2 ¥ 5 min,
2¥ SSC with 0.1% SDS) and twice in high stringency condi-
tions (68°C, 2 ¥ 15 min, 0.5¥ SSC with 0.1% SDS), where 1¥
SSC comprises 150 mM sodium chloride and 50 mM sodium
acetate, pH 7.0. Bound probe was detected using the DIG
immunological detection kit (Roche) as per manufacturers’
instructions.
Western blot analysis of T. brucei cell lysates
Polyclonal antisera against T. brucei TRYS were raised in
adult male Wistar rats. An initial injection of 100 mg of puriﬁed
antigen, emulsiﬁed in complete Freund’s adjuvant, was fol-
Table 1. Upper case letters refer to nucleotides corresponding to gene sequences in T. brucei; lower case refers to additional sequences used
in generating constructs.
Primer name Primer sequence
5′UTR-NotI_s 5′-ataagaatgcggccgcTGTGGTTGTTGTTTC-3′
5′UTR-HindIII/PmeI_as 5′-gtttaaacttacggaccgtcaagcttTTGTTTCAATTGCTTTTCC-3′
3′UTR-PmeI/BamHI_s 5′-gacggtccgtaagtttaaacggatccCACAACCCTTCCGTTTTG-3′
3′UTR-NotI_as 5′-ataagtaagcggccgcGGAATAAACATAAAGC-3′
TbTRYS-HindIII_s 5′-cggaaggagaaagcttatgggcagcagccat-3′
TbTRYS-BamHI_as 5′-ggatccCTACATTTGAATACGTACGGGACCAAACGGAGATTCGAGCCCAGTGATGAGCTT-3′
TbTRYS(C57A) mut_s 5′-cttttctgcggtttcaaataccaagctgtagaattt-3′
TbTRYS(C57A) mut_as 5′-aaattctacagcttggtatttgaaaccgcagaaaag-3′
Restriction endonuclease sites are underlined and mutations used to generate a amidase-dead TRYS are indicated in bold.
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in Freund’s incomplete adjuvant at 2 week intervals.
Trypanosoma brucei whole cell extracts (1 ¥ 10
7 parasites
per lane) were separated by SDS/PAGE and subsequently
transferred onto nitrocellulose. After blocking with 7%
skimmed milk in phosphate buffered saline (PBS) for 1 h,
blots were incubated with either T. brucei TRYS (1:700 dilu-
tion) or T. brucei PTR1 (1:500) (Sienkiewicz et al., 2008)
polyclonal antiserum for 1 h, washed in PBS containing 0.1%
(v/v) Tween-20, and then incubated with a secondary anti-
body [rabbit anti(rat IgG)] (Dako, Ely, UK; 1:10 000 dilution).
Immunoblots were developed using the ECL plus (enhanced
chemiluminescence) system from GE Healthcare (Piscat-
away, NJ, USA).
Drug discovery
Ahigh-throughput screening campaign of 63 000 compounds
led to the identiﬁcation of several novel chemical classes of
T. brucei TRYS inhibitor. Chemical development of one
of these lead compounds led to the identiﬁcation of com-
pound DDU 86439 (N-(3-(dimethylamino)propyl)-2-(3-(3-
ﬂuorophenyl)-1H-indazol-1-yl)acetamide) (patent pending)
which inhibited recombinant TRYS with a potency of
0.045 mM and inhibited the growth of bloodstream trypano-
somes with an EC50 of 6.9  0.2 mM. DDU 86439 was pre-
pared in ﬁve synthetic steps from indazole. Brieﬂy, indazole
was iodinated at the three position, as previously described
(Edwards et al., 2003). The resultant aryl iodide served
as the substrate for a Suzuki coupling reaction with
3-ﬂuorophenylboronic acid in an analogous manner to that
previously described (El Kazzouli et al., 2005). The indazole
was then N
1-alkylated by treatment with sodium hydride and
ethyl bromoacetate. The resulting crude ester was hydro-
lysed by treatment with sodium hydroxide in water/
tetrahydrofuran. Following acidic workup, the product
carboxylic acid was puriﬁed by silica column chromatography.
The amide synthesis was accomplished via standard carbo-
diimide chemistry utilizing N-(3-Dimethylaminopropyl)-
N′-ethylcarbodiimide, 1-Hydroxybenzotriazole, N,N-
Diisopropylethylamine and 3-(dimethylamino)-1-propylamine
to furnish the title compound, which was puriﬁed by silica
column chromatography. Full details of chemical synthesis of
this and other inhibitors are to be published elsewhere.
Analysis of intracellular thiols
To determine the effect of inhibitor DDU 86439 on intracellu-
lar thiol levels, cultures containing 1 ¥ 10
5 bloodstream trypa-
nosomes ml
-1 were incubated with varying concentrations of
inhibitor DDU 86439 equivalent to 0.5, 1.0, 1.5 and 2¥ the
previously determined EC50 (6.9  0.2 mM). Following incuba-
tion for 72 h, cells (1 ¥ 10
8) were collected by centrifugation
(900 g, 10 min, 4°C), washed once in ice-cold PSG buffer
(PBS, pH 8.0, 1.5% (w/v) glucose and 0.5 mg ml
-1 BSA) and
derivatised with monobromobimane, as described previously
(Shim and Fairlamb, 1988). Acid-soluble thiols were sepa-
rated by ion-paired, reverse phase HPLC on an ion-paired
Ultrasphere C18 column using a Dionex Ultimate 3000 instru-
ment ﬁtted with a Dionex RF-2000 ﬂuorometer.
In vivo studies
Wild-type and transgenic bloodstream T. brucei parasites
were cultured in the absence of selectable drugs (hygromy-
cin, blasticidin, puromycin and G418) for 24 h prior to infec-
tion of mice. During this time, cDKO cells were grown in the
presence or absence of 1 mgm l
-1 tetracycline. These para-
sites were then used to infect groups of ﬁve mice (dosed with
and without doxycycline respectively) by a single intraperito-
neal injection of 10
4 parasites in 0.2 ml of HMI9-T medium.
The plus doxycycline group of animals were dosed with doxy-
cycline in their drinking water (0.2 mg ml
-1 in a 5% sucrose
solution) for 5 days prior to infection and freshly prepared
every second day for the duration of the experiment. Animals
were inspected daily for clinical signs of infection and wet
smears of tail blood were examined microscopically. Parasi-
taemia was determined using a Neubauer haemocytometer,
as previously described (Sienkiewicz et al., 2008). Mice that
exceeded a parasitaemia > 10
8 ml
-1 were humanely killed,
because prior experience indicated that animals would
succumb to an overwhelming infection by the following day.
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